Eli Lilly announced that Mufengda (tilpoxetine injection) has been approved by the China National Medical Products Administration (NMPA) as the first and currently the only prescription drug for the treatment of moderate to severe obstructive sleep apnea (OSA) in obese adult patients. Tipoxetine can improve sleep disorders in obese adult patients with moderate to severe obstructive sleep apnea. The use of this indication requires control of diet and increased exercise.